Based on these findings, BELLE-3 was to assess the efficacy of buparlisib or placebo in combination with fulvestrant in hormone-receptor-positive, HER2-negative, advanced breast cancer patients with PIK3CA-mutant and wild-type status detected in ctDNA [124]. This evidence concerns the gene NR4A1 and breast cancer.